Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Medicine > Endocrinology > Flashcards

Endocrinology Flashcards

1
Q

WHO diagnostic criteria for DM

A

If symptomatic: fasting glucose >=7.0mmol/L or random glucose >=11.1mmol/L

If asymptomatic the above criteria must be demonstrated on two separate occasions

OR:
HbA1c >= 6.5% (48) is diagnostic
HbA1c 6-6.5% ?prediabetes
HbA1c <6.0% DM excluded

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Side effects of insulin and MoA

A

Hypoglyaemia, weight gain, lipodystrophy (alternate injection sites)
Beta blockes reduce hypoglycaemic awareness

MoA: Glucose utilisation and glycogen synthesis, Inhibits lipolysis, Reduces muscle protein loss, Increases cellular uptake of K+ (NaKATPase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Side effects of metformin and mechanism of action

A

GI upset, lactic acidosis, cant use in eGFR <30

MoA: Increases insulin sensitivity, and decreases hepatic gluconeogenesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Side effects of sulfonylureas (gliclazide) and MoA

A

Hypoglycaemia, weight gain, hyponatraemia

MoA: Stimulates pancreatic beta cells to secrete insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Side effects of thiazolidinediones (pioglitazone)

A

Weight gain, fluid retention (Contraindicated in HF)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Side effects of SGLT-2 inhibitors (-gliflozins) and MoA

A

UTI, weight loss

MoA: Inhibits reabsorption of glucose in the kidney (hence UTI as a side effect)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Side effects of GLP-1 agonists

A

N+V, pancreatitis, weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Management of T2DM

A

Lifestyle modification first.
Metformin first line drug.
If HbA1c still >7.5% (58), add a gliptin or sulfonylurea or pioglitazone or SGLT-2 inhibitor (dual therapy)
If still >7.5% (58) add another of the above drugs (triple therapy)
If still not effective use insulin.
Or:
If triple therapy not effective, not tolerated or if contraindicated AND BMI >35 do metformin + sulfonylurea + GLP-1 mimetic (eg. exenatide)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Guidelines for monitoring T1DM

A

Check HbA1c every 3-6m, target <6.5%
Self monitor at least 4 times/day (before each meal and before bed) - monitor more if ill, having hypoglycaemic episodes, sport, pregnancy
Target 5-7mmol/L on waking and 4-7mmol/L before meals/other times of the day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Management of T1DM

A

Multiple daily injection basal-bolus insulin regimen:
twice-daily insulin detemir is regime of choice, with rapid-acting insulin before meals (novorapid)

Consider adding metformin if BMI >= 25

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

T2DM risk factor modification

A

BP: target <140/80 (or <130/80 if end-organ damage), ACE-i first line regardless of age

QRISK2 >10% (10year cardiovascular risk of >10%) should be offered 20mg atorvastatin OD (primary prevention)
If secondary prevention (known IHD/PAD) give atorvastatin 80mg OD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Sick day rules in DM

A 
Check BMs at least every 4 hours, drink at least 3L in 24h,  if unable to eat then drink sugary drinks, pt's should be able to check Ketone levels
Continue oral hypoglycaemics even if not eating (stress response increases BMs) - possible exception is metformin (risk of dehydration -> lactic acidosis -> AKI)
Continue insulin (risk of DKA if stopped)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Presentation of diabetic foot disease

A

neuropathy: loss of sensation
Ischaemia: absent foot pulses, reduced ABPI, intermittent claudication
Calluses, ulceration, Charcot’s arthropathy, cellulitis, osteomyelitis, gangrene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Diabetic foot disease sceening

A

At least annually. Palpate for both dorsalis pedis pulse and posterior tibial artery pulse
Use a 10g monofilament on various parts of the sole to check sensation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

DKA diagnostic criteria

A

Glucose >11 or known DM
pH <7.3
Bicarb <15
Ketones >3 or urine ketones ++

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Management of DKA

A

Fluid replacement (approx 6-8L dehydrated)

Correct hypokalaemia - 1L 0.9% NaCl over first hour and then add KCl into subsequent bags
If K >5.5 in first 24hr dont add KCl into bags
If K 3.5-5.5 add 40mmol/L into bags
If K <3.5 seek senior help

IV fixed rate insulin: 0.1unit/kg/hr
When glucose <15 add 5% dextrose infusion

Long acting insulin should be continued, short acting insulin should be stopped

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Complications of DKA

A

Gastric stasis
VTE
Arrhythmias (hyperkalaemia, hypokalaemia)
Iatrogenic complications due to fluid therapy: cerebral oedema, hypokalaemia, hypoglycaemia)
ARDS
AKI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Cerebral oedema and DKA

A

Due to IV fluid therapy too much too quickly
Children/young adults most vulnerable - 1:1 nursing to monitor neuro-observations, headache, irritability, visual disturbance, focal neurology
Usually 4-12hrs following commencement of treatment
CT head and senior review
Mannitol or hypertonic saline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

DM and DVLA

A

If on insulin/sulfonylureas, pt can drive as long as: not had severe hypoglycaemia in prev 12m, driver has full hypoglycaemic awareness, regular BM monitoring at least BD and at times relevent to driving, no other debarring complications of DM

No need to inform DVLA if on tablets that don’t induce hypoglycaemia, or if diet-controlled DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Hyperosmolar hyperglycaemic state

  • at risk population group
  • where are they managed
  • clinical features
A

Typically presents in the elderly with T2DM
Medical emergency - managed in HDU or ITU
Osmotic diuresis, severe dehydration, electrolyte deficiencies
Clinical features: fatigue, lethargy, N+V, altered consciousness, headaches, papilloedema, weakness, hyperviscosity (MI, stroke, peripheral artery thrombosis), dehydration, hypotnesion, tachycardia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Complications of hyperosmolar hyperglycaemic state

A

MI, stroke, peripheral artery thrombosis

Less common: seizures, cerebral oedema, central pontine myelinolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Pathophysiology of hyperosmolar hyperglycaemic state

A

Hyperglycaemia results in osmotic diuresis with associated loss of Na and K
Severe vol depletion -> raised serum osmolarity (>320mosmol/kg) -> serum hyperviscosity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Diagnosis of hyperosmolar hyperglycaemic state

A 
Hypovolaemia
Marked hyperglycaemia (>30) without significant ketones or acidosis
Significantly raised serum osmolarity (>320mosm/kg)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Management of hyperosmolar hyperglycaemic state

A

Normalise osmolality gradually, replace fluids and electrolytes, normalise blood glucose gradually

Fluid losses estimated to be 100-220ml/kg (7-16L in 70Kg)
IV 0.9% saline is first line (rate depends on patient and comorbidities) - aim to replace 50% of losses in first 12hrs and the remaining in the next 12h

Vigorous fluid replacement alone will result in gradual decline in plasma glucose and serum osmolarity

Insulin should NOT be used because rapid decline in glucose may be harmful

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Causes of hypoglycaemia

A

Insulinoma
Self administration of insulin/sulphonylureas
Liver failure
Addisons disease
Alcohol
Nesidioblastosis in children (beta cell hypertrophy)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Insulinoma features

  • what is it
  • clinical features
A

Most common pancreatic endocrine tumour (islets of langerhans)

Hypoglycaemia early in the morning or just before meal
Rapid weight gain
high insulin, raised proinsulin:insulin ratio
High C peptide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Diagnosis and treatment of insulinoma

A

Supervised, prolonged fasting (up to 72 hours) - hypoglycaemia and increased plasma insulin
CT pancreas

Treatment: surgical excision (diazoxide and somatostatin if not eligible for surgery)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Clinical features of thyrotoxicosis

A

Symptoms: diarrhoea, weight loss, increased appetite, swear, heat intolerance, palpitations, tremor, irritability, anxiety, oligomenorrhoea/infertility

Signs: tachycardia/AF, warm moist skin, fine tremor, palmar erythema, thin hair, lid lag, lid retraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Causes of thyrotoxicosis

A

Graves, toxic nodular goitre, toxic adenoma, ectopic thyroid tissue, exogenous (levothyroxine overdose), acute phase of subacute (De Quervain’s) thyroiditis, amiodarone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Investigations of thyrotoxicosis

A 
TSH down, T4 and T3 up
Thyroid autoantibodies (anti-thyroid peroxidase antibodies, TSH receptor autoantibodies, thyroglobulin autoantibodies)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Treatment of thyrotoxicosis

A

Beta blockers for rapid control of symptoms
Carbimazole (SE: agranulocytosis, get urgent FBC if sore throat/infection)
Radioiodone
Thyroidectomy - risk of damage to recurrent laryngeal nerve (hoarseness) and hypoparathyroidism. Pt will become hypothyroid so levothyroxine required

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Features of thyroid eye disease

A

Exophthalmos, conjunctival oedema, optic disc swelling, ophthalmoplegia
Inability to close the eyelids -> sore dry eyes -> exposure keratopathy

NO SPECS

  1. No signs or symptoms
  2. Ocular irritation (dryness, FB sensation)
  3. Soft tissue involvement (conjunctival chemosis/oedema)
  4. Proptosis (exophthalmos)
  5. Extraocular muscle fibrosis
  6. Corneal exposure and ulceration if severe
  7. Sight loss (due to corneal ulceration, compressive optic neuropathy or ↑ IOP)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Management of thyroid eye disease

A

topical lubricants, steroids, radiotherapy, surgery

Smoking is the most important risk factor (stop smoking to prevent TED)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

TFT results for

  • thyrotoxicosis
  • primary hypothyroidism
  • secondary hypothyroidism
  • sick euthyroid syndrome
  • subclinical hypothyroidism
  • poor compliance with thyroxine
  • steroid therapy
A
  • thyrotoxicosis: TSH low free T4 high
  • primary hypothyroidism: TSH high free T4 low
  • secondary hypothyroidism: TSH low free T4 low
  • sick euthyroid syndrome: TSH low free T4 low
  • subclinical hypothyroidism: TSH high free T4 normal
  • poor compliance with thyroxine: TSH high free T4 low
  • steroid therapy: TSH low free T4 normal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Graves disease features

A

Commonest cause of thyrotoxicosis
Typically seen in women aged 30-50y
TSH receptor stimulating autoantibodies, and anti-thyroid peroxidase autoantibodies

Typical features of thyrotoxicosis, plus: exophthalmos, ophthalmoplegia, pretibial myxoedema, thyroid acropachy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Clinical features of thyroid storm

A

Fever >38.5, tachycardia, confusion, agitation, N+V, HTN, HF, abnormal LFTs (jaundice)

37
Q

Primary vs secondary vs congenital hypothyroidism

A

Primary - problem with the thyroid gland (eg. autoimmune disease affecting thyroid tissue)

Secondary - disorder of the pituitary gland or lesion compressing pituitary

Congenital - thyroid dysgenesis or thyroid dyshormonogenesis

38
Q

Clinical features of hypothyroidism

A

Weight gain, lethargy, cold intolerance, dry/cold/yellowish skin, non-pitting oedema, dry/coarse hair, constipation, menorrhagia, decreased deep tendon reflexes, carpal tunnel syndrome

39
Q

Subacute (DeQuervains) thyroiditis

  • precipitating event
  • investigations
  • management
A
  • Following a viral infection
  • Ix: thyroid scintigraphy (globally reduced uptake of iodine-131)
  • Mx: usually self-limiting, thyroid pain may respond to aspirin/NSAIDs, steroids if severe or is hypothyroidism develops
40
Q

Causes of primary and secondary hypothyroidism

A

Primary: Hashimotos (Most common. Autoimmune. Women more common), DeQuervains thyroiditis, Riedel thyroiditis, after thyroidectomy/radioiodine, drug therapy (lithium, amiodarone, carbimazole), dietary iodine deficiency

Secondary: Down’s, Turner’s, coeliac, pituitary failure (compression from external features or from pituitary itself)

41
Q

Management of hypothyroidism

A

Levothyroxine
Check TFTs 8-12wks after thyroxine dose change
Therapeutic goal is normalisation of TSH (0.5-2.5)
Increase levothyroxine by 25-50mcg in pt who becomes pregnant (monitor carefully)

42
Q

Side effects and interactions of levothyroxine

A

SE: hyperthyroidism, reduced bone mineral density, worsening angina, AF

Interactions: iron and calcium carbonate -> reduce absorption of levothyroxine (give at least 4 hours apart)

43
Q

Congenital hypothyroidism

  • risks if not diagnosed
  • features
  • screening
A

If not diagnosed and treated within first four weeks it causes irreversible cognitive impairment

Features: prolonged neonatal jaundice, delayed mental and physical milestones, short stature, puffy face, macroglossia, hypotonia

Children are screened at 5-7 days using heel prick test

44
Q

Actions of PTH

A

Released in response to hypocalcaemia
Acts on the bone to increase osteoclast activity -> bone releases calcium and phosphate into the blood
Acts at the kidney to increase calcium reabsorption and increase phosphate excretion
Also acts at the kidney to increase hydroxylation and activation of Vit D -> vit D then acts to increase calcium absorption from the intestine

45
Q

What is the difference between PTH and PTHrp

A

PTHrp has all the same effects as PTH however it cannot activate vitamin D

46
Q

Primary vs secondary vs tertiary vs malignant hyperparathyroidism (calcium and PTH levels)

A

Primary: increased calcium levels and increased PTH levels.
Secondary: reduced calcium levels and increased PTH levels.
Tertiary: increased calcium, significantly increased PTH.
Malignant: increased calcium, and reduced PTH (PTHrp is not detected in PTH assay)

47
Q

Primary hyperparathyroidism

  • causes
  • presentation
  • tests
  • treatment
A

Causes: adenoma, hyperplasia, parathyroid cancer

Presentation: often asymptomatic, detected with hypercalcaemia on routine tests
Other signs/sx: tiredness, weakness, depression, pancreatitis, ulcers, bone pain, fractures, osteopenia/osteoporosis, dehydration, renal stones, abdo pain, thirsty, HTN

Tests: increased calcium and PTH, reduced phosphate, increased ALP (bone activity), 24hr urinary calcium increased. Technetium-MIBI subtraction scan
X-ray may show pepperpot skull.
Check BP.

Treatment: total parathyroidectomy is definitive Mx. Cinacalcet (calcimimetic) offered if surgery inappropriate (increased sensitivity of parathyroid cells to Ca)

48
Q

Secondary hyperparathyroidism

  • causes
  • treatment
A

Causes: reduced vit D intake, CKD.
hypocalcaemia leads to excessive secretion of PTH
Treatment: correct cause. Phosphate binders, vit D, cinacalcet, parathyroidectomy

49
Q

Tertiary hyperparathyroidism

-causes

A

Causes: occurs after prolonged secondary hyperparathyroidism, causing glands to become hyperplastic and release PTH regardless of calcium levels -> increased calcium, significantly increased PTH.
Often seen in CKD.

50
Q

Cancers releasing PTH-rp

A

Squamous cell lung cancers
Breast cancers
Renal cell carcinomas

51
Q

Primary hypoparathyroidism

  • causes
  • presentation
  • tests
  • treatment
A

-causes: autoimmune gland failure, congenital (Di George)
-presentation: hypocalcaemia, cramps, perioral numbness, Trousseau’s sign (carpopedal spasm), Chvostek sign
-tests: low calcium, high phosphate (or normal), normal ALP, low PTH
Treatment: calcium supplements + calcitriol
-tests

52
Q

Secondary hypoparathyroidism causes

A

Radiation, surgery (thyroidectomy, parathyroidectomy), hypomagnesaemia (Mg required for PTH secretion)

53
Q

Pseudohypoparathyroidism vs pseudopseudohypoparathyroidism

A

pseudo: Failure of target cells to respond to PTH. Short metacarpals, round face, short stature, calcified basal ganglia.
pseudopseudo: morphological features of pseudo but with normal biochemistry

54
Q

Multiple endocrine neoplasia type 1 vs type 2a vs type 2b associated features (3Ps, 2Ps, 1P)

A

MEN1: hyperparathyroidism, pituitary tumours, pancreatic tumours (insulinoma, gastrinoma). Most common presentation is hypercalcaemia

MEN2a: hyperparathyroidism, phaeochromocytoma (also medullary thyroid cancer)

MEN2b: phaeochromocytoma (also medullary thyroid cancer and neuromas)

MEN1 gene is a tumour suppressor gene, MEN2 gene is a proto-oncogene

55
Q

Cortisol negative feedback

A

Corticotropin releasing factor released from hypothalamus -> stimulates ACTH secretion from pituitary -> stimulates glucocorticoid (cortisol) production and androgen production by adrenal cortex

56
Q

Causes of Cushing’s syndrome

A 
Oral steroids
Cushings disease (pituitary adenoma -> increased ACTH)
Ectopic ACTH (SCLC, carcinoid tumours)
Adrenal adenoma/hyperplasia
McCune-Albright syndrome
57
Q

Signs and symptoms of Cushings syndrome

A

Symptoms: weight gain, mood change (depression, irritability, psychosis), hirsutism, irregular menses, erectile dysfunction, acne, proximal weakness, recurrent achilles rupture

Signs: central obesity, plethoric, moon face, buffalo hump, supraclavicular fat distribution, skin and muscle atrophy, bruises, purple striae, osteoporosis, hypertension, hyperglycaemia, infections, poor healing

Signs of a cause (eg. abdo mass)

58
Q

Cushings syndrome investigations

A

Overnight dexamethasone suppression test (dex 1mg PO at midnight, serum cortisol measured at 8am)
Normal: suppressed cortisol
Cushings syndrome due to oral steroids: cortisol not suppressed by low dose dex
Cushings disease: cortisol not suppressed by low dose dex, but suppressed by high dose dex
Ectopic ACTH: not suppressed by low or high dose dex

24hr urinary free cortisol

Other results:
Hypokalaemic metabolic alkalosis
Impaired glucose tolerance
HTN

59
Q

Treatment of Cushings syndrome

A
  • treat underlying cause
  • cushings disease: remove pituitary adenoma (trans-sphenoidally)
  • adrenalectomy
60
Q

What is addison’s disease

A

Primary adrenocortical insufficiency, caused by destruction of adrenal cortex leading to glucocorticoid (cortisol) and mineralocorticoid (aldosterone) deficiency

61
Q

Clinical features of addisons disease

A

lethargy, weakness, anorexia, N+V, weight loss, salt craving, hyperpigmentation of palmar creases, vitilligo, loss of pubic hair in women, low BP, hypoglycaemia, hyponatraemia, hyperkalaemia

62
Q

Causes of hypoadrenalism

A 
Addisons disease
TB
Mets
Meningococcal septicaemia
HIV
Antiphospholipid syndrome
Pituitary disorders (tumour, irradiation, infiltration) -> secondary hypoadrenalism
Long term exogenous gluocorticoid therapy
63
Q

Investigations for addisons disease

A

Synacthen test: plasma cortisol measures before and 30 mins after giving synthetic ACTH.
No reponse in addisons because the ACTH has no where to act (due to adrenal destruction).

Alternative: 9am serum cortisol (low in addisons but not diagnostic)

Other results: hyperkalaemia, hyponatraemia, hypoglycaemia, met acidosis, hypercalcaemia, uraemia, anaemia, eosinophilia

64
Q

Treatment and follow up for addisons disease

A

A combination of hydrocortisone and fludrocortisone (PO)

Wear a steroid bracelet
Add 5-10mg hydrocortisone before exercise
Double steroids in illness

Follow up: yearly BP, yearly U+E, watch for other autoimmune diseases

65
Q

Addisonian crisis

  • causes
  • presentation
  • management
A

Causes: sepsis, surgery, adrenal haemorrhage, steroid withdrawal

Presentation: shock (tachycardia, hypotension, vasoconstriction, oliguria, weak, confused, comatose), hypoglycaemia

Management: hydrocortisone 100mg IM/IV, normal saline fluid boluses or with dextrose if hypoglycaemia, continue hydrocortisone 6 hourly until patient is stable
Convert to oral after 24 hours and reduce back to maintenance over 3-4 days

66
Q

Causes of primary hyperaldosteronism

A

Conn’s syndrome (adrenal adenoma)

Bilateral idiopathic adrenal hyperplasia

67
Q

Clinical features of primary hyperaldosteronism

A

Hypertension
Hypokalaemia (muscle weakness, cramps, paraesthesia, polyuria, polydipsia)
Alkalosis

68
Q

Investigations for primary hyperaldosteronism

A

First-line: plasma aldosterone/renin ratio (high aldosterone alongside low renin = diagnosis)

High resolution CT abdomen and adrenal vein sampling used to differentiate between unilateral and bilateral sources of aldosterone excess

69
Q

Management of primary hyperaldosteronism

A

Adrenal adenoma: surgery

Bilateral adrenocortical hyperplasia: aldosterone antagonist (spironolactone)

70
Q

Phaeochromocytoma

  • what is it
  • associations
  • features
  • tests
  • management
A
  • Rare catecholamine secreting tumour
  • 10% are familial, associated with MEN type 2, neurofibromatosis, and von Hippel-Lindau syndrome
  • Features: HTN, headaches, palpitations, sweating, anxiety
  • tests: 24hr urinary colection of metanephrines, and CT abdo
  • Mx: surgery is definitive, but pt should be medically stabilised first with alpha blocker (phenoxybenzamine) followed by a beta blocker (propranolol)
71
Q

Features of Klinefelters

A 
Primary hypogonadism (47XXY)
Tall
Small, firm testes
Lack of secondary sexual characteristics
Infertile
Gynaecomastia
Elevated gonadotrophin levels but low testosterone

Diagnosed by karyotype

72
Q

Kallmann’s syndrome

A 
Secondary hypogonadism (hypogonadotrophic hypogonadism)
X-linked recessive (males)
Lack of smell
Delayed puberty
Hypogonadism
Sex hormones low
LH and FSH levels inappropriately low/normal
normal/above average height

Cleft lip/palate and visual/hearing defects may be seen

73
Q

Congenital adrenal hyperplasia

  • inheritance pattern
  • what is it
A

A group of autosomal recessive disorders affecting adrenal steroid biosynthesis

Different types: 21-hydroxylase deficiency (90%), 11-beta hydroxylate deficiency, 17-hydroxylase deficiency

CAH affects adrenal steroid biosynthesis -> in response to resultant low cortisol levels the anterior pituitary secretes high levels of ACTH -> adrenal androgen production -> virilisation in females and precocious puberty in males

74
Q

Indications, administration and side effects of GH therapy

A

Indications: proven GH deficiency, Turners, Prader-Willi, chronic renal insufficiency before puberty

Administration: SC

SE: headache, benign intracranial HTN, fluid retention

75
Q

Acromegaly causes

A

Excess GH secondary to a pituitary adenoma (95% of cases), or due to ectopic GHRH or GH production by tumours (eg. pancreatic tumour)

76
Q

Acromegaly features

A

Coarse facial appearance, spade like hands, increased shoe size, large tongue, prognathism (jaw protrusion), interdental spaces, excessive sweating, oily skin, raised prolactin (galactorrhoea)
Pituitary tumour features (hypopituitarism, headache, bitemporal hemianopia)
Some patients also have MEN-1

77
Q

Complications of acromegaly

A

HTN, diabetes, cardiomyopathy, colorectal cancer

78
Q

Acromegaly investigations

A

Serum IGF-1 levels are first-line (raised in acromegaly)
If IGF-1 levels are raised, diagnosis can then be confirmed by doing OGTT test (GH should be suppressed in hyperglycaemia, in acromegaly there is no suppression of GH following OGTT)

(IGF-1 = insulin-like growth factor 1)

Pituitary MRI may show a pituitary tumour

79
Q

Acromegaly management

A

Trans-sphenoidal surgery is first-line in majority of patients

Somatostatin analogue (octreotide) inhibits release of GH (may be used as surgery adjunct)

Dopamine agonists (bromocriptine) effective in some patients

80
Q

Pituitary adenoma investigations

A

Pituitary blood profile (GH, prolactin, ACTH, FH, LSH, TFTs)
Formal visual field testing
MRI brain with contrast

there are different types of pituitary adenomas - prolactinoma is the most common, followed by non-secreting adenomas

81
Q

Pituitary adenoma DDx

A

Pituitary hyperplasia, craniopharyngioma, meningioma, brain mets, lymphoma, hypophysitis, vascular malformation (eg. aneurysm)

82
Q

Management of pituitary adenoma

A

Hormonal: bromocriptine/dopamine agonist (first line for prolactinoma), octreotide/somatostatin analogue

Surgery (trans-sphenoidal transnasal hypophysectomy)

Radiotherapy

83
Q

Features of excess prolactin in men vs. women

A

Men: impotence, loss of libido, galactorrhoea
Women: amenorrhoea, galactorrhoea

84
Q

Causes of raised prolactin

A

Prolactinoma, pregnancy, oestrogens, physiological (stress, exercise, sleep), acromegaly, PCOS, primary hypothyroidism

Drugs: metoclopramide, domperidone, phenothiazines, haloperidol, SSRI, opioids

Dopamine inhibits prolactin release, therefore dopamine antagonists promote prolactin secretion

85
Q

Side effects of glucocorticoids

A
  • Head: insomnia, mania, depression, psychosis, intracranial HTN
  • Eyes: glaucoma, cataracts
  • Blood/immuno: neutrophilia, immunosuppression (infections, reactivation of TB)
  • MSK: growth suppression in children, osteoporosis, proximal myopathy, avascular necrosis of femoral head
  • GI: peptic ulcer, acute pancreatitis
  • Endocrine: DM, weight gain, hirsutism, hyperlipidaemia, Cushing’s syndrome
86
Q

nephrogenic vs cranial diabetes insipidus

  • causes of nephrogenic
  • causes of cranial
A

Passage of large volumes of dilute urine due to impaired water absorption by the kidney, because of:

Nephrogenic: impaired response of the kidney to ADH
-causes: inherited, hypokalaemia, hypercalcaemia, lithium, demeclocycline, CKD, post-obstructive uropathy

Cranial: reduced ADH secretion from the posterior pituitary
-causes: idiopathic, congenital, tumour, mets, trauma, hypophysectomy, sarcoidosis, haemorrhage, meningoencephalitis

87
Q

Symptoms of diabetes insipidus

A

polyuria, polydipsia, dehydration, hypernatraemia

88
Q

Tests for diabetes insipidus

A

U+E (hypernatraemia, hypokalaemia), hypercalcaemia, glucose (exclude DM), serum and urine osmolalities

Diagnosis: 8-hour water deprivation test (no drink for 8 hours -> measure urine osmolality -> should increase in the presence of dehydration, but doesnt if DI)
Can then differentiate between cranial and nephrogenic by giving desmopressin at the end of the 8 hours -> if osmolality then increases (=cranial), if it doesnt (=nephrogenic)

89
Q

Management of diabetes insipidus

A

Cranial: desmopressin (synthetic ADH)

Nephrogenic: treat cause. If it persists trial bendroflumethiazide

Medicine (15 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions